bosutinib
Bosutinib is a drug used to treat Chronic Myeloid Leukemia, Healthy, and Breast Cancer. Bosutinib is being actively studied in 16 studies and prior, has been studied in 20.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Pfizer | Pfizer Investigational Site | Haruhisa Inoue |
| Wyeth is now a wholly owned subsidiary of Pfizer | M D Anderson Cancer Center | Nagla Abdel Karim |
| M.D. Anderson Cancer Center | Roswell Park Cancer Institute | Sheldon Jordan |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Recruiting
- Healthy Participants
- Bosutinib capsule
- Bosutinib
- Brussels, Bruxelles-capitale, Région DE, BelgiumBrussels Clinical Research Unit
2022-02-08
Feb 8, 2022N
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +7 more
- Bosutinib
- Pemetrexed
- Augusta, GeorgiaAugusta University Georgia Cancer Center
2021-07-31
Jul 31, 2021P
Recruiting
- Chronic Myelogenous Leukemia
- Bosutinib
- Shibuya-ku, Japan(unnamed)
2020-12-29
Dec 29, 2020M
Completed
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- +6 more
- Bosutinib
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-03-25
Mar 25, 2022K
Recruiting
- Amyotrophic Lateral Sclerosis
- Bosutinib
- Kyoto, Japan
- +3 more
2021-02-03
Feb 3, 2021S
Recruiting
- Chronic Myeloid Leukemia
- Bosutinib
- Ropeginterferon
- Aalborg, Denmark
- +17 more
2022-04-04
Apr 4, 2022M
Terminated
- Accelerated Phase Chronic Myelogenous Leukemia (CML)
- +3 more
- Axitinib
- +2 more
- Houston, TexasM D Anderson Cancer Center
2020-11-17
Nov 17, 2020G
Recruiting
- Metastatic Breast Cancer
- +2 more
- Palbociclib
- +2 more
- Washington, District of ColumbiaLombardi Comprehensive Cancer Center
2022-01-17
Jan 17, 2022P
Completed
- Leukemia, Chronic Myelogenous
- Bosutinib
- Toyoake-City, Aichi, Japan
- +20 more
2022-03-04
Mar 4, 2022P
M
Terminated
- Blasts Under 15 Percent of Bone Marrow Nucleated Cells
- +4 more
- Bosutinib
- Laboratory Biomarker Analysis
- Houston, TexasM D Anderson Cancer Center
2020-04-22
Apr 22, 2020P
Completed
- Chronic Myeloblastic Leukaemia
- Bosutinib
- Gran Canaria, Spain
- +12 more
2020-04-28
Apr 28, 2020N
Not yet recruiting
- Chronic Myelogenous Leukemia
- Asciminib single agent
- +6 more
- (no location specified)
2021-11-25
Nov 25, 2021P
Completed
- Chronic Myeloid Leukaemia
- Bosutinib
- +4 more
- Budapest, HungaryPfizer
2022-03-09
Mar 9, 2022N
Enrolling by invitation
- Mild Cognitive Impairment
- Dementia
- bosutinib
- Santa Monica, CaliforniaNeurological Associates of West LA
2021-02-25
Feb 25, 2021U
Active, not recruiting
- CML, Chronic Phase
- +4 more
- Bosutinib
- +3 more
- Chapel Hill, North CarolinaUNC Hospital
2021-08-27
Aug 27, 2021N
Active, not recruiting
- Chronic Myeloid Leukemia
- +2 more
- Imatinib
- +3 more
- Moscow, Russian FederationNational Research Center for Hematology
2020-10-01
Oct 1, 2020U
Completed
- Leukemia
- +3 more
- Bosutinib
- +2 more
- Monza, Italy/MB, Italy
- +1 more
2020-11-03
Nov 3, 2020C
Recruiting
- Philadelphia Chromosome Positive CML
- +3 more
- Bosutinib
- Birmingham, Alabama
- +40 more
2022-02-28
Feb 28, 2022P
Completed
- Chronic Myeloid Leukaemia
- Bosutinib
- Liverpool, Merseyside, United Kingdom
- +2 more
2019-05-01
May 1, 2019G
Active, not recruiting
- Chronic Myeloid Leukemia
- Bosutinib
- Alessandria, Italy
- +44 more
2022-01-04
Jan 4, 2022P
Terminated
- Previously Treated PH + CML
- Bosutinib
- Los Angeles, California
- +47 more
2021-12-02
Dec 2, 2021P
Completed
- Chronic Myeloid Leukemia
- bosutinib
- Orlando, Florida
- +90 more
2021-07-23
Jul 23, 2021C
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +12 more
- Edmonton, Alberta, Canada
- +9 more
2022-03-14
Mar 14, 2022N
Active, not recruiting
- Chronic Myelogenous Leukemia
- Asciminib
- Bosutinib
- Chicago, Illinois
- +87 more
2022-03-21
Mar 21, 2022